<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004065</url>
  </required_header>
  <id_info>
    <org_study_id>99-037</org_study_id>
    <secondary_id>CDR0000067267</secondary_id>
    <secondary_id>NCI-T99-0035</secondary_id>
    <secondary_id>UCLA-0206019</secondary_id>
    <nct_id>NCT00004065</nct_id>
  </id_info>
  <brief_title>Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer</brief_title>
  <official_title>A Phase I Trial of 17-N-Allylamino-17-Demethoxy Geldanamycin (17-AAG, NSC #330507) Daily X 5 in Patients With Advanced Cancer Therapeutic Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die.

      PURPOSE: This phase I trial is studying the side effects and best dose of
      17-N-allylamino-17-demethoxygeldanamycin in treating patients with refractory advanced solid
      tumors or hematologic cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of 17-N-allylamino-17-demethoxygeldanamycin
           (17-AAG) in patients with refractory or advanced solid tumors or hematologic
           malignancies.

        -  Evaluate the effects of this drug on the expression of signaling proteins present on an
           individual patient's cancer at the start of treatment and, if possible, post treatment.

      OUTLINE: This is a two-phase, dose-escalation, multicenter study. Patients are stratified
      according to disease (chronic myelogenous leukemia [CML] or Philadelphia chromosome [Ph]+
      acute lymphoblastic leukemia [ALL] vs solid tumor).

      Patients receive 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) IV over 60-90 minutes
      twice weekly. Courses repeat every 12 weeks in the absence of disease progression (after at
      least 2 courses for CML or Ph+ ALL patients) or unacceptable toxicity.

        -  Accelerated phase: Single patients receive escalating dose levels of 17-AAG until one
           patient experiences a first course grade 3 or greater toxicity or two different patients
           experience grade 2 toxicity during any course.

        -  Standard phase: Cohorts of 3-6 patients in each stratum receive escalating doses of
           17-AAG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the
           dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting
           toxicity.

      PROJECTED ACCRUAL: Approximately 51 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Bladder Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tanespimycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of 1 of the following:

               -  Histologically confirmed advanced primary or malignant solid tumor refractory to
                  standard therapy or for which no curative standard therapy exists

                    -  Progressive disease evidenced by 1 of the following:

                         -  Non-prostate cancer (including, but not limited to, breast, ovary, head
                            and neck, non-small cell lung, bladder, kidney, colon, stomach, or
                            malignant melanoma)

                              -  Development of new lesions or an increase in existing lesions

                              -  No increase in a biochemical marker (e.g., carcinoembryonic
                                 antigen, CA-15-3, or an increase in symptoms) as sole measure of
                                 disease

               -  Prostate cancer (androgen independent) meeting the following criteria:

                    -  Progressing metastatic disease on bone scan, CT scan, or MRI

                    -  Metastatic disease and rising prostate-specific antigen (PSA) values meeting
                       1 of the following criteria:

                         -  At least 3 rising PSA values obtained at least 1 week apart = 2 rising
                            values more than 1 month apart with at least 25% increase over the
                            range of values

                    -  Serum testosterone less than 30 ng/mL

                    -  Castrate status should be maintained by medical therapies if orchiectomy has
                       not been performed

                    -  Progressive disease must be evident off antiandrogen therapy if received
                       prior to study entry

                    -  Registered to protocol MSKCC-9040

               -  Cytologically confirmed chronic, accelerated, or blastic phase chronic
                  myelogenous leukemia (CML) or Philadelphia chromosome (Ph)-positive acute
                  lymphoblastic leukemia (ALL) refractory to standard therapy or for which no
                  curative therapy exists

                    -  Progressive disease evidenced by 1 of the following:

                         -  Accelerated or blastic phase disease that is not responsive to standard
                            therapy or loss of hematologic response to imatinib mesylate while
                            remaining in chronic phase for CML

                         -  Relapsed or refractory after treatment with standard chemotherapy and
                            imatinib mesylate for Ph-positive ALL

          -  No active CNS or epidural tumor

          -  Hormone receptor status:

               -  Not specified

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Sex:

          -  Not specified

        Menopausal status:

          -  Not specified

        Performance status:

          -  Karnofsky 70-100%

        Life expectancy:

          -  At least 6 months

        Hematopoietic:

          -  WBC greater than 3,500/mm^3

          -  Platelet count greater than 100,000/mm^3

          -  No restrictions based on peripheral blood counts for CML and Ph-positive ALL

        Hepatic:

          -  Bilirubin no greater than 1.2 times upper limit of normal (ULN)

          -  AST less than 1.5 times ULN

          -  Prothrombin time normal

        Renal:

          -  Creatinine no greater than 1.5 times ULN OR

          -  Creatinine clearance greater than 60 mL/min

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

          -  Ejection fraction greater than 45% by radionuclide cardiac angiography

          -  No ventricular aneurysm or other abnormal wall motion

          -  No reversible defect by thallium stress test if any of the following conditions are
             present:

               -  Ejection fraction less than 45% on radionuclide angiocardiography

               -  Worrisome but nonexclusive cardiovascular history

               -  Abnormal echocardiogram

          -  Patients with the following history or clinical findings require additional diagnostic
             testing:

               -  Significant Q waves (greater than 3 mm or greater than one-third of the height of
                  the QRS complex)

               -  ST elevation or depressions of greater than 2 mm that are not attributable to
                  hypertension strain

               -  Absence of regular sinus rhythm

               -  Bundle branch block

               -  Requirement for diuretics for reasons other than hypertension or digoxin for
                  reasons other than atrial fibrillation

               -  Prior mild to moderate congestive heart failure

          -  No New York Heart Association class III or IV heart disease

          -  No angina pectoris

          -  No uncontrolled hypertension or intermittent claudication

          -  No severe debilitating valvular disease

        Pulmonary:

          -  No severe debilitating pulmonary disease

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No active infection requiring IV antibiotics

          -  No symptomatic peripheral neuropathy grade 2 or higher

          -  No other severe medical conditions that would increase risk for toxicity

          -  No allergy to eggs or egg products

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 4 weeks since prior biologic therapy (including interferon for CML) and
             recovered

        Chemotherapy:

          -  At least 4 weeks since prior chemotherapy (3 days for hydroxyurea for CML or ALL) and
             recovered

          -  No other concurrent chemotherapy

        Endocrine therapy:

          -  See Disease Characteristics

          -  At least 4 weeks since prior endocrine therapy and recovered

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy and recovered

          -  Concurrent radiotherapy to localized disease sites not being used to evaluate
             antitumor response allowed

          -  No concurrent radiotherapy to only measurable lesion

        Surgery:

          -  See Disease Characteristics

          -  Prior orchiectomy allowed

          -  No concurrent surgery

        Other:

          -  At least 3 days since prior imatinib mesylate for CML or ALL

          -  At least 4 weeks since prior investigational anticancer drugs and recovered

          -  At least 4 weeks since prior palliative treatment for metastatic disease

          -  No concurrent ketoconazole, warfarin, verapamil, miconazole, or erythromycin

          -  No other concurrent investigational drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard I. Scher, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 20, 2013</last_update_submitted>
  <last_update_submitted_qc>June 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>stage III bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>untreated metastatic squamous neck cancer with occult primary</keyword>
  <keyword>recurrent metastatic squamous neck cancer with occult primary</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>stage III ovarian germ cell tumor</keyword>
  <keyword>stage IV ovarian germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage III squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage III basal cell carcinoma of the lip</keyword>
  <keyword>stage III mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage III adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV basal cell carcinoma of the lip</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>stage IV adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>recurrent basal cell carcinoma of the lip</keyword>
  <keyword>recurrent verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent mucoepidermoid carcinoma of the oral cavity</keyword>
  <keyword>recurrent adenoid cystic carcinoma of the oral cavity</keyword>
  <keyword>stage III squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage III lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the oropharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the oropharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the oropharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage III lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage III squamous cell carcinoma of the larynx</keyword>
  <keyword>stage III verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the larynx</keyword>
  <keyword>recurrent verrucous carcinoma of the larynx</keyword>
  <keyword>stage III squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage III esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>stage IV esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent inverted papilloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent midline lethal granuloma of the paranasal sinus and nasal cavity</keyword>
  <keyword>recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity</keyword>
  <keyword>borderline ovarian surface epithelial-stromal tumor</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>stage III verrucous carcinoma of the oral cavity</keyword>
  <keyword>recurrent salivary gland cancer</keyword>
  <keyword>stage IV salivary gland cancer</keyword>
  <keyword>stage III salivary gland cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

